Search Within

Martin Henner Voss

  1. "2015"
Formats
  1. Meeting Abstract (20)
  2. Journal Article (4)
Groups
  1. Department of Medicine (24)
  2. Genitourinary Oncology Service (24)
  3. Solid Tumor Oncology Division (24)
  4. Radiology, Department of (7)
  5. Biostatistics Service (6)
  6. Epidemiology and Biostatistics (6)

More Groups

People
  1. Robert Motzer (10)
  2. James Hsieh (7)
  3. Darren Feldman (4)
  4. Sujata Patil (4)
  5. Yingbei Chen (4)
  6. Almedina Djesevic (3)

More People

Years
  1. 2015 (24)
Publications
  1. Journal of Clinical Oncology (14)
  2. BJU International (4)
  3. European Journal of Cancer (2)
  4. American Society of Clinical Oncology Educational Book (1)
  5. Cancer Chemotherapy and Pharmacology (1)
  6. Clinical Genitourinary Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (15)
  2. Wiley Blackwell (4)
  3. Elsevier Inc. (3)
  4. Oxford University Press (1)
  5. Springer (1)

Results (24)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Challenging the treatment paradigm for advanced renal cell carcinoma: A review of systemic and localized therapies
    Journal Article

    Bex, A.; Larkin, J.; Voss, M.
    American Society of Clinical Oncology Educational Book (2015)

    Fulltext@MSK | Save
  • The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Plimack, E.; Rini, B.; Bhatt, R. S.; Alter, R.; Beck, J. T.; Mutyaba, M.; Pappas, K.; Wilson, D.; Zhang, X.; more...
    BJU International (2015)

    Fulltext@MSK | Save
  • The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Plimack, E.; Rini, B.; Alter, R.; Bhatt, R. S.; Beck, J. T.; Mutyaba, M.; Pappas, K.; Wilson, D.; Zhang, X.; more...
    BJU International (2015)

    Fulltext@MSK | Save
  • Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next-generation sequencing (NGS): Results from RECORD-3
    Meeting Abstract

    Hsieh, J. J.; Chen, D.; Wang, P. I.; Chen, Y. B.; Redzematovic, A.; Marker, M.; Patel, P.; Chevinsky, M.; Bhanot, U.; Pinciroli, P.; more...
    BJU International (2015)

    Fulltext@MSK | Save
  • Expanded cohort results from CheckMate 016: A Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Hammers, H. J.; Plimack, E. R.; Lnfante, J. R.; Rini, B. I.; McDermott, D. F.; Ernstoff, M. S.; Voss, M. H.; Sharma, P.; Pal, S. K.; Razak, A.; more...
    BJU International (2015)

    Fulltext@MSK | Save
  • A phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    McDermott, D. F.; Infante, J. R.; Chowdhury, S.; Voss, M. H.; Motzer, R. J.; Perini, R. F.; Morosky, A.; Zheng, F. F.; White, B. C.; Wang, Q.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer
    Meeting Abstract

    Voss, M.; Gordon, M. S.; Mita, M.; Rini, B.; Makker, V.; Macarulla, T.; Smith, D.; Kwak, E. L.; Cervantes, A.; Puzanov, I.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor
    Meeting Abstract

    Zanna, C.; Vaslin, A.; Voss, M. H.; Heist, R. S.; Hierro, C.; Supko, J. G.; Nakai, K.; Ishii, N.; Menetrey, A.; Roubaudi-Fraschini, M. C.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Plimack, E. R.; Rini, B. I.; Atkins, M. B.; Alter, R.; Bhatt, R. S.; Beck, J. T.; Mutyaba, M.; Pappas, K. M.; Wilson, D.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary features
    Meeting Abstract

    Voss, M. H.; Chen, Y. B.; Chaim, J.; Coskey, D. T.; Woo, K.; Redzematovic, A.; Wang, P.; Lee, W.; Patil, S.; Molina, A. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save